^
    Back
    Association details:
    Biomarker:GNAQ Q209P
    Cancer:Uveal Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    omipalisib (GSK2126458) (mTOR inhibitor, PI3K inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Cancer Res
    Title:

    Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ and GNA11 Dependent Manner

    Excerpt:
    Figure 2B shows GNAQ and GNA11 mutant cell growth to be more sensitive to MEKi treatment than wild-type cells, reaching 50% of half-maximal growth inhibition at ∼1 log less nanomolar concentration....Mutant GNAQ [Q209L (92.1, MEL202), Q209P (MEL270)], mutant GNA11 [Q209L (OMM1, UPMD1, UPMD2)] or wild-type (MEL285, MEL290) uveal melanoma cells were treated with MEKi alone, PI3Ki alone, or the combination of MEKi + PI3Ki...
    DOI:
    10.1158/1078-0432.CCR-11-3227